Advertisement
U.S. markets closed

XTL Biopharmaceuticals Ltd. (XTLB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.8452+0.0363 (+4.49%)
At close: 02:11PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.8089
Open0.8452
Bid0.7652 x 1000
Ask0.8970 x 3200
Day's Range0.8452 - 0.8452
52 Week Range0.7500 - 1.5400
Volume2,505
Avg. Volume3,627
Market Cap4.606M
Beta (5Y Monthly)0.81
PE Ratio (TTM)N/A
EPS (TTM)-0.4000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for XTLB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • XTL Biopharmaceuticals Ltd.
    Daily – Vickers Top Buyers & Sellers for 02/21/2024The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel

    Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets consists of an IP portfolio relating to hCDR1 for the treatment of systemic lupus erythematosus, or SLE, and Sjögren’s syndrome, or SS, today addressed the status of the Company's continued and uninterrupted activity in Israel against the background of the recent severe terrorist attack in the south o

  • GlobeNewswire

    XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

    Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets consists of an IP portfolio relating to hCDR1 for the treatment of systemic lupus erythematosus, or SLE, and Sjögren’s syndrome, or SS, today announced that the Company received a written notification (the "Notice") from the Nasdaq Stock Market LLC (“Nasdaq”) on October 18, 2023, notifying the Company